Therefore, it is reasonable that the crosstalk between Smarcd1 and Notch1 contributes to glioma chemoresistance potentially via the existence of GSCs, and strategies targeting pathways involving GSC to break up TMZ chemoresistance are the latest frontier of current GBM treatment. Here, SMARCD1 is linked to glioma.